Literature DB >> 20556587

Aortic cell apoptosis in rat primary aldosteronism model.

Yongji Yan1, Jinzhi Ouyang, Chao Wang, Zhun Wu, Xin Ma, Hongzhao Li, Hua Xu, Zheng Hu, Jun Li, Baojun Wang, Taoping Shi, Daojing Gong, Dong Ni, Xu Zhang.   

Abstract

This study aimed to determine whether aldosterone could induce vascular cell apoptosis in vivo. Thirty-two male rats were randomly divided into 4 groups: vehicle (control), aldosterone, aldosterone plus eplerenone or hydralazine. They were then implanted with an osmotic mini-pump that infused either aldosterone or the vehicle. Systolic blood pressure (SBP) was measured weekly by the tail-cuff method. After 8 weeks, plasma aldosterone concentration (PAC) and renin activity (PRA) were determined by radioimmunoassay. Aortic apoptosis was examined by TUNEL assay. The levels of cytochrome c and caspase-3 were determined by Western blotting and the expression of Bax and Bcl-2 was detected by immunohistochemistry and Western blotting. The results showed that as compared with control group, aldosterone-infused rats exhibited: (1) an increase in SBP; (2) significantly elevated PAC with depressed PRA; (3) elevated aortic vascular cell apoptosis accompanied with higher levels of cytochrome c and activated caspase-3; and (4) significantly up-regulated Bax protein with down-regulated Bcl-2. These effects of aldosterone were significantly inhibited after co-administration with eplerenone but not with hydralazine. It was concluded that aldosterone induced vascular cell apoptosis by its direct effect on the aorta via mineralocorticoid receptors and independently of blood pressure, which may contribute to aldosterone-mediated vascular injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556587     DOI: 10.1007/s11596-010-0362-3

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  29 in total

1.  Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors.

Authors:  J W Funder; P T Pearce; R Smith; J Campbell
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

2.  Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53.

Authors:  Jan H von der Thüsen; Bart J M van Vlijmen; Rob C Hoeben; Mark M Kockx; Louis M Havekes; Theo J C van Berkel; Erik A L Biessen
Journal:  Circulation       Date:  2002-04-30       Impact factor: 29.690

Review 3.  Mechanisms of mineralocorticoid action.

Authors:  Peter J Fuller; Morag J Young
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

Review 4.  Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis.

Authors:  Ozgur Kutuk; Huveyda Basaga
Journal:  Apoptosis       Date:  2006-10       Impact factor: 4.677

Review 5.  DNA damage, p53, apoptosis and vascular disease.

Authors:  John Mercer; Melli Mahmoudi; Martin Bennett
Journal:  Mutat Res       Date:  2007-03-01       Impact factor: 2.433

6.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

7.  Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src.

Authors:  Glaucia E Callera; Rhian M Touyz; Rita C Tostes; Alvaro Yogi; Ying He; Sam Malkinson; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2005-02-07       Impact factor: 10.190

8.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.

Authors:  T Münzel; S Kurz; S Rajagopalan; M Thoenes; W R Berrington; J A Thompson; B A Freeman; D G Harrison
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

9.  In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion.

Authors:  E Durand; A Scoazec; A Lafont; J Boddaert; A Al Hajzen; F Addad; M Mirshahi; M Desnos; A Tedgui; Z Mallat
Journal:  Circulation       Date:  2004-05-17       Impact factor: 29.690

10.  Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide.

Authors:  C G Schnackenberg; W J Welch; C S Wilcox
Journal:  Hypertension       Date:  1998-07       Impact factor: 10.190

View more
  5 in total

1.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.

Authors:  Guido Zavatta; Guido Di Dalmazi; Carmine Pizzi; Giovanni Bracchetti; Cristina Mosconi; Caterina Balacchi; Uberto Pagotto; Valentina Vicennati
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.633

2.  Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.

Authors:  Yongji Yan; Chao Wang; Yiqin Lu; Huijie Gong; Zhun Wu; Xin Ma; Hongzhao Li; Baojun Wang; Xu Zhang
Journal:  J Physiol Biochem       Date:  2017-11-21       Impact factor: 4.158

3.  Effect of fibulin-5 on aldosterone-induced apoptosis in human ascending aortic smooth muscle cells.

Authors:  Yongji Yan; Xujie Liu; Xuanchen Li; Xuan Zhou; Chaozhi Yang; Jintao Tian; Jun Pu; Xiaoqun Niu
Journal:  Exp Ther Med       Date:  2021-06-23       Impact factor: 2.447

Review 4.  Atrial Fibrillation and Aortic Ectasia as Complications of Primary Aldosteronism: Focus on Pathophysiological Aspects.

Authors:  Martina Bollati; Chiara Lopez; Fabio Bioletto; Federico Ponzetto; Ezio Ghigo; Mauro Maccario; Mirko Parasiliti-Caprino
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 5.  The role of regulated necrosis in endocrine diseases.

Authors:  Wulf Tonnus; Alexia Belavgeni; Felix Beuschlein; Graeme Eisenhofer; Martin Fassnacht; Matthias Kroiss; Nils P Krone; Martin Reincke; Stefan R Bornstein; Andreas Linkermann
Journal:  Nat Rev Endocrinol       Date:  2021-06-16       Impact factor: 47.564

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.